381 related articles for article (PubMed ID: 16739327)
1. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
Brivio F; Fumagalli L; Lissoni P; Nardone A; Nespoli L; Fattori L; Denova M; Chiarelli M; Nespoli A
Anticancer Res; 2006; 26(1B):599-603. PubMed ID: 16739327
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy in radical surgery of colorectal carcinoma].
Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
[TBL] [Abstract][Full Text] [Related]
3. Improvement of 10-year survival by Japanese radical lymph node dissection in patients with Dukes' B and C colorectal cancer: a 17-year retrospective study.
Mukai M; Ito I; Mukoyama S; Tajima T; Saito Y; Nakasaki H; Sato S; Makuuchi H
Oncol Rep; 2003; 10(4):927-34. PubMed ID: 12792747
[TBL] [Abstract][Full Text] [Related]
4. Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma.
Bovo G; Brivio F; Brenna A; Fumagalli L; Perego P; Brivio O; Uggeri F; Lavorato F; Bratina G
Pathologica; 1995 Apr; 87(2):135-8. PubMed ID: 8532404
[TBL] [Abstract][Full Text] [Related]
5. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy.
Kamoshida S; Matsuoka H; Ishikawa T; Maeda K; Shimomura R; Inada K; Tsutsumi Y
Jpn J Clin Oncol; 2004 Oct; 34(10):594-601. PubMed ID: 15591457
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
[TBL] [Abstract][Full Text] [Related]
8. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production.
O'Hara RJ; Greenman J; MacDonald AW; Gaskell KM; Topping KP; Duthie GS; Kerin MJ; Lee PW; Monson JR
Clin Cancer Res; 1998 Aug; 4(8):1943-8. PubMed ID: 9717823
[TBL] [Abstract][Full Text] [Related]
9. Prognosis in Duke's B colorectal carcinoma: the Jass classification revisited.
De Quay N; Cerottini JP; Albe X; Saraga E; Givel JC; Caplin S
Eur J Surg; 1999 Jun; 165(6):588-92. PubMed ID: 10433145
[TBL] [Abstract][Full Text] [Related]
10. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
[TBL] [Abstract][Full Text] [Related]
11. The impact of surgeon and pathologist on lymph node retrieval in colorectal cancer and its impact on survival for patients with Dukes' stage B disease.
Evans MD; Barton K; Rees A; Stamatakis JD; Karandikar SS
Colorectal Dis; 2008 Feb; 10(2):157-64. PubMed ID: 17477849
[TBL] [Abstract][Full Text] [Related]
12. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
[TBL] [Abstract][Full Text] [Related]
13. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection.
Heriot AG; Marriott JB; Cookson S; Kumar D; Dalgleish AG
Br J Cancer; 2000 Mar; 82(5):1009-12. PubMed ID: 10737381
[TBL] [Abstract][Full Text] [Related]
14. Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery.
Caprotti R; Brivio F; Fumagalli L; Nobili C; Degrate L; Lissoni P; Parolini D; Messina G; Colciago M; Scotti M; Uggeri F
Anticancer Res; 2008; 28(3B):1951-4. PubMed ID: 18630487
[TBL] [Abstract][Full Text] [Related]
15. Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients.
Brivio F; Lissoni P; Alderi G; Barni S; Lavorato F; Fumagalli L
Oncology; 1996; 53(4):263-8. PubMed ID: 8692528
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis.
Gardini A; Ercolani G; Riccobon A; Ravaioli M; Ridolfi L; Flamini E; Ridolfi R; Grazi GL; Cavallari A; Amadori D
J Surg Oncol; 2004 Jul; 87(1):46-52. PubMed ID: 15221919
[TBL] [Abstract][Full Text] [Related]
17. [Meta-analysis of postoperative adjuvant chemotherapy for Dukes' B colorectal carcinoma].
Wan XB; Pan ZZ; Chen G; Li LR; Wan DS
Ai Zheng; 2005 May; 24(5):600-4. PubMed ID: 15890106
[TBL] [Abstract][Full Text] [Related]
18. Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline.
Brivio F; Lissoni P; Rovelli F; Nespoli A; Uggeri F; Fumagalli L; Gardani G
Hepatogastroenterology; 2002; 49(44):385-7. PubMed ID: 11995457
[TBL] [Abstract][Full Text] [Related]
19. Indication and efficacy of adjuvant chemotherapy with oral fluoropyrimidines for dukes' B colorectal cancer.
Yoshimatsu K; Umehara A; Ishibashi K; Yokomizo H; Yoshida K; Fujimoto T; Watanabe K; Ogawa K
Anticancer Res; 2006; 26(4B):3089-93. PubMed ID: 16886639
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients.
Brivio F; Lissoni P; Gilardi R; Ferrante R; Vigore L; Curzi L; Uggeri F; Nespoli A; Fumagalli L
J Biol Regul Homeost Agents; 2000; 14(3):200-3. PubMed ID: 11037053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]